Few medications have changed weight loss as quickly as semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound). Millions of people have started them in the past few years, and many are losing more weight, more quickly, than any diet ever allowed. Then, a few months in, some of them notice something they did not expect: more hair in the brush, a wider parting, a thinner ponytail.
It is an understandably alarming moment, and it raises two very different questions. Is the medication itself attacking the hair, or is something else happening? And more importantly for anyone who has waited years for this weight loss: will the hair come back? The answers depend on how the body reacts to rapid weight change, and on what was already happening to the hair before the first injection.
GLP-1 Hair Loss at a Glance
Hair loss is a recognised side effect of semaglutide and tirzepatide, reported by about 3–5% of people in the weight-loss trials compared with 1% on placebo, and far more often in women. In most cases it is telogen effluvium, a temporary shedding triggered by rapid weight loss rather than by a direct effect of the drug on the follicle. It usually settles within six to nine months once weight stabilises; hair loss that does not recover is most often pattern hair loss that the shedding has made visible.
Why do GLP-1 medications cause hair loss?
Rapid weight loss triggers telogen effluvium
Every hair on the scalp follows its own cycle: a long growth phase lasting years, a short transition, and a resting phase of about three months before the hair falls out and a new one starts. Normally only around one in ten hairs is resting at any time. A significant physical stress, such as surgery, a high fever, childbirth or fast weight loss, can push a large number of growing hairs into the resting phase at once. About two to three months later, they shed together. This is telogen effluvium.
Semaglutide and tirzepatide reduce appetite strongly, and many people lose 10–20% of their body weight within a year. To the body, that is a major stress. The label for tirzepatide makes the connection directly: in the trials, hair loss in Zepbound-treated patients was associated with weight reduction.
Eating less means fewer nutrients for the follicle
Growing hair is metabolically demanding, and it is one of the first things the body economises on when intake drops. People on GLP-1 medications often eat much smaller portions, sometimes skip meals entirely, and may struggle to eat enough protein. Low protein, low iron stores and other nutritional deficiencies that cause hair loss can deepen and prolong the shedding.
Is the drug itself to blame?
Researchers have not shown that GLP-1 medications damage hair follicles directly. A 2025 scoping review of nine studies found that most reports lacked a dermatological diagnosis; where the type of hair loss was described, it was mainly telogen effluvium and androgenetic alopecia. The authors concluded that a causal relationship cannot yet be confirmed, while still treating the more than 1,000 reports to the US Food and Drug Administration as a signal that deserves attention. Another 2025 systematic review found conflicting results across studies. The weight-loss explanation remains the most consistent one.
How common is hair loss on Ozempic, Wegovy, Mounjaro and Zepbound?
The most reliable figures come from the official US prescribing information, which reports side effects from the large placebo-controlled weight-loss trials.
| Medication (weight-loss dose) | Hair loss on medication | Hair loss on placebo |
|---|---|---|
| Semaglutide 2.4 mg (Wegovy label) | 3% | 1% |
| Tirzepatide 5 mg (Zepbound label) | 5% | 1% |
| Tirzepatide 10 mg | 4% | 1% |
| Tirzepatide 15 mg | 5% | 1% |
Ozempic and Mounjaro contain the same active ingredients as Wegovy and Zepbound but are used at diabetes doses, where weight loss is usually smaller. Interestingly, a review of cases reported to the FDA found that hair loss was reported more often when GLP-1 medications were used for diabetes than for weight management, so the risk is not limited to the weight-loss brands.
Why women are affected more often
The difference between the sexes is striking. In the tirzepatide trials, hair loss was reported by 7.1% of women compared with 0.5% of men on the medication, and 1.3% of women compared with 0% of men on placebo. The label does not explain the difference. Likely contributors are that women often notice shedding sooner with longer hair, are more prone to low iron stores, and may already have early female pattern hair loss that the shedding unmasks.
Is GLP-1 hair loss permanent?
For most people, no. But the answer depends on which of two situations you are in, and they can look identical at the start.
Temporary shedding: telogen effluvium
In telogen effluvium the follicles are not damaged; they have simply been pushed into a resting phase together. Shedding typically starts two to four months after weight loss speeds up and slows once weight stabilises. New hairs then grow back from the same follicles, at roughly a centimetre a month, so it takes six to nine months, and sometimes up to a year, before the hair looks as full as it did. Signs that point to telogen effluvium:
- Shedding across the whole scalp, not in one area.
- Many hairs with a small white bulb at the root.
- Short new hairs appearing along the hairline and parting after a few months.
Stopping the medication is usually not necessary to recover, and the decision should always be made with the prescribing doctor, not because of the hair alone.
Hair loss that does not come back: unmasked pattern hair loss
Shedding sometimes reveals a second problem. If you were already developing male or female pattern hair loss, heavy shedding can make it visible all at once. When the shedding stops, the areas affected by pattern loss, typically the temples and crown in men or the top of the scalp in women, do not fully recover. This is not caused by the medication; it is male pattern baldness or female pattern hair loss that would have appeared anyway, and it needs treatment of its own.
| Telogen effluvium | Unmasked pattern hair loss | |
|---|---|---|
| Where | Whole scalp, evenly | Hairline, temples and crown (men); top of scalp and parting (women) |
| Hairs in the thinning area | Normal thickness | Finer, shorter, miniaturised |
| Course | Recovers within 6–12 months | Continues without treatment |
| What helps | Time, steady weight, adequate nutrition | Medication, scalp treatments, hair transplant |
A trichoscopic examination of the scalp is the quickest way to tell them apart: miniaturised hairs in a typical pattern point to pattern hair loss, while normal hairs and diffuse shedding point to telogen effluvium.
How to protect your hair while taking a GLP-1 medication
Keep weight loss steady
The faster the weight comes off, the bigger the stress on the hair cycle. If shedding is heavy, it is worth discussing the dose and pace of weight loss with the doctor who prescribes the medication. Never stop or change the dose on your own.
Protect protein and micronutrient intake
With a much smaller appetite, every meal matters more. Prioritise protein at each meal and ask your doctor or a dietitian how much you need. A blood test for ferritin, vitamin D, B12 and thyroid function is sensible if shedding starts, so that any deficiency can be corrected rather than guessed at.
Support the scalp, not just the diet
While the hair cycle resets, in-clinic treatments such as PRP hair treatment and hair mesotherapy can support the scalp and the regrowing hairs. If pattern hair loss has been unmasked, prescription medication for that condition is the main treatment, and it can usually be combined safely with a GLP-1 medication under a doctor’s supervision.
Be gentle with your hair
During the shedding phase, avoid tight hairstyles, aggressive brushing and harsh chemical treatments. They do not cause telogen effluvium, but they can break hairs that are already fragile and make the thinning look worse.
Hair transplant after weight loss: when is the right time?
Many people who reach their goal weight on a GLP-1 medication then want to deal with hair that did not come back. A transplant can work very well, but timing matters.
Wait until both your weight and your hair are stable
A transplant is planned when hair loss is stable, not while the scalp is still shedding. During telogen effluvium the scalp looks thinner than it really is, so the bald area, the density behind the hairline and even the donor area can be misjudged. Waiting until weight has been stable for several months and the shedding has settled shows which areas are genuinely lost and which will recover on their own.
Check your donor area and nutrition first
The donor area at the back of the scalp can shed too during telogen effluvium. Once it has recovered, its density can be assessed accurately, which decides how many grafts are available. Correcting any iron, protein or vitamin deficiency before surgery also supports healing and graft growth afterwards.
Tell your surgeon about the medication
GLP-1 medications slow the emptying of the stomach. Share the name and dose with your clinic before surgery, as you may be given specific instructions about doses and fasting before a procedure involving sedation.
Dr. Erdoğan’s View: Lose the Weight, Keep Perspective on the Hair
Shedding on semaglutide or tirzepatide is common, visible and frightening, but in most people it is the body reacting to rapid weight loss, and the hair grows back once weight settles. It is rarely a reason to give up a treatment that is improving your health.
What deserves attention is the hair that does not come back. If the hairline, crown or parting still look thin a year after the shedding began, that is very likely pattern hair loss, and it can be treated, or restored, like any other case once your weight and your scalp are stable.
Reached Your Goal Weight but Not Your Old Hairline?
If your weight has been stable for a while and some areas have still not filled in, an assessment can show whether the hair is still recovering or whether those follicles have been lost to pattern hair loss. Send photos of your hairline, crown and the back of your scalp, together with the name of your medication and when the shedding started, and you will get an honest view of whether to wait, treat or restore. If a transplant is the next step, see how a hair transplant in Turkey is timed and planned after major weight loss, what a hair transplant in Turkey costs, and what the hair transplant package includes.
Frequently asked questions
Does Ozempic cause hair loss?
Hair loss is a recognised side effect of semaglutide. In the weight-loss trials, 3% of people on semaglutide 2.4 mg reported hair loss compared with 1% on placebo. It is usually temporary shedding linked to rapid weight loss.
Does tirzepatide (Mounjaro or Zepbound) cause hair loss?
Yes, in a minority of people. Hair loss was reported by 4–5% of people on tirzepatide in the weight-loss trials compared with 1% on placebo, and much more often in women (7.1%) than in men (0.5%).
Will my hair grow back after Ozempic?
In most cases, yes. Telogen effluvium usually settles once weight stabilises, and the hair regrows over six to nine months, sometimes up to a year. Areas that do not recover are usually affected by pattern hair loss and need separate treatment.
Should I stop my GLP-1 medication because of hair loss?
Not without speaking to your prescribing doctor. The shedding usually resolves without stopping, and the health benefits of the treatment often outweigh a temporary change in hair density. Adjusting the pace of weight loss or correcting deficiencies may help.
Can I have a hair transplant while taking Ozempic or Mounjaro?
It is possible, but it is best planned once your weight and hair have been stable for several months. Tell the clinic about the medication in advance, as you may receive specific instructions before surgery.
This article is for information only and does not replace an in-person medical examination.
Sources
- US Food and Drug Administration. ZEPBOUND (tirzepatide) prescribing information, section 6.1 Adverse Reactions. accessdata.fda.gov
- US Food and Drug Administration. WEGOVY (semaglutide) prescribing information, section 6.1 Adverse Reactions. accessdata.fda.gov
- Rojas Lopez RF, et al. Alopecia as an emerging adverse effect associated with GLP-1 receptor agonists for weight loss: a scoping review. Cureus. 2025;17(8):e90021. doi:10.7759/cureus.90021
- Alsuwailem OA, et al. Hair loss associated with GLP-1 receptor agonist use: a systematic review. Cureus. 2025;17(9):e92454. doi:10.7759/cureus.92454
- Daniel S, et al. A retrospective comparative analysis of cutaneous adverse reactions in GLP-1 agonist therapies. J Drugs Dermatol. 2025;24(4):413–415. doi:10.36849/JDD.8605